Hengrui Pharma Gets Nod to Trial Drug Combination for Hepatocellular Carcinoma
() -- Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276), through its subsidiaries, received approval from China's National Medical Products Administration for the clinical trials of a drug combination for the treatment of hepatocellular carcinoma, according to a Shanghai bourse filing on Friday. The pharmaceutical